MIRA Pharmaceuticals (NASDAQ:MIRA – Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.03) earnings per share (EPS) for the quarter, FiscalAI reports.
MIRA Pharmaceuticals Stock Down 5.0%
MIRA Pharmaceuticals stock traded down $0.04 during trading hours on Wednesday, hitting $0.74. 26,431 shares of the company traded hands, compared to its average volume of 131,984. The firm has a market cap of $31.04 million, a P/E ratio of -0.57 and a beta of 1.54. The firm’s 50-day simple moving average is $0.90 and its two-hundred day simple moving average is $1.04. MIRA Pharmaceuticals has a 1-year low of $0.60 and a 1-year high of $2.45.
Institutional Trading of MIRA Pharmaceuticals
Institutional investors have recently made changes to their positions in the stock. XTX Topco Ltd bought a new position in shares of MIRA Pharmaceuticals in the second quarter valued at approximately $26,000. Creative Planning bought a new stake in MIRA Pharmaceuticals during the second quarter worth approximately $27,000. Fifth Third Bancorp acquired a new stake in MIRA Pharmaceuticals in the fourth quarter worth approximately $30,000. Two Sigma Investments LP lifted its position in MIRA Pharmaceuticals by 129.8% in the third quarter. Two Sigma Investments LP now owns 45,703 shares of the company’s stock worth $62,000 after purchasing an additional 25,816 shares during the period. Finally, BlackRock Inc. acquired a new stake in MIRA Pharmaceuticals in the second quarter worth approximately $232,000. 35.16% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Check Out Our Latest Report on MIRA Pharmaceuticals
About MIRA Pharmaceuticals
MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.
Read More
- Five stocks we like better than MIRA Pharmaceuticals
- GE Vernova’s AI Power Boom Faces a Profit Test
- Cardinal Health Earnings: Can Perfection Get Priced In Twice?
- Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
- Legacy Jet Builders Stall While Embraer Accelerates to New Highs
Receive News & Ratings for MIRA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MIRA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
